Claimed effect · Lixisenatide

Does Lixisenatide help with major cardiovascular events?

A
Grade A — established in humans1 large RCT (ELIXA, n=6,068) · effect size: not measurable
Short answerEstablished in humans. 1 large RCT (ELIXA, n=6,068) point the same way: no measurable effect, or none yet shown. In people with type 2 diabetes and a recent acute coronary syndrome, lixisenatide neither increased nor reduced major cardiovascular events — non-inferior to placebo, not superior. The first GLP-1 outcomes trial, and a neutral one.

What the studies show

In people with type 2 diabetes and a recent acute coronary syndrome, lixisenatide neither increased nor reduced major cardiovascular events — non-inferior to placebo, not superior. The first GLP-1 outcomes trial, and a neutral one.

“A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of lixisenatide to placebo (P<0.001) but did not show superiority (P=0.81).”

Verbatim, from the abstractPfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA). N Engl J Med, 2015;373:2247–2257

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Lixisenatide is a short-acting GLP-1 receptor agonist derived from exendin-4, approved for type 2 diabetes since 2013 and now sold mainly in combination with insulin glargine. Its cardiovascular-outcomes trial in 6,068 people after a heart attack was neutral. In 2024 a French phase 2 trial found that a year of lixisenatide slowed motor progression in early Parkinson's disease by about three points on the standard scale, with nausea in nearly half. It is prescription-only; the standalone product has been withdrawn in some markets.

Lixisenatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Lixisenatide proven to help with major cardiovascular events?
Yes, as far as human trials can show it: 1 large RCT (ELIXA, n=6,068). LYO grades this outcome A.
What studies are behind the grade?
In people with type 2 diabetes and a recent acute coronary syndrome, lixisenatide neither increased nor reduced major cardiovascular events — non-inferior to placebo, not superior. The first GLP-1 outcomes trial, and a neutral one.
Is Lixisenatide approved for this?
Lixisenatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Lixisenatide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →